Boehringer Ingelheim, a leading Germany-based biopharmaceutical company, has strengthened its commitment to improving healthcare access in Kenya by signing a Memorandum of Understanding (MoU) with the Mission for Essential Drugs and Supplies (MEDS). This partnership aims to enhance the availability of affordable treatments for type 2 diabetes and hypertension while supporting local healthcare systems.
Launched in Kenya in September 2022, Boehringer Ingelheim’s ‘Access to Healthcare’ initiative seeks to bridge medical gaps in underserved communities. The program provides essential treatments at subsidized rates, encourages medication adherence, and collaborates with local healthcare institutions to improve disease management.
With plans to scale the program further across the region, the initiative has already made a significant impact. Over 1,500 patients have been enrolled, more than 200 physicians have been engaged, and 15 healthcare facilities across Kenya have joined the effort.
Non-communicable diseases (NCDs), including diabetes and hypertension, remain a major public health challenge in Kenya, contributing to approximately 27% of all deaths. Through this expanded collaboration, Boehringer Ingelheim and MEDS aim to strengthen the fight against chronic illnesses by ensuring broader access to quality healthcare solutions.